Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | XDH | P47989 | 1/20 | 0.46 |
| ▸ | LTA4H | P09960 | 4/20 | 0.45 |
| ▸ | SCN4A | P35499 | 2/20 | 0.42 |
| ▸ | MCL1 | Q07820 | 4/20 | 0.42 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | PSD | A5PKW4 | 1/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.40 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3669956 | 0.84 | MEN1 (0.43) | NPC1RAB9ATSHR | |
| SCHEMBL1008901 | 0.84 | MEN1 (0.46) | NPC1RAB9ATSHR | |
| Hydrochloric Acid SCHEMBL1307189 | 0.82 | MEN1 (0.44) | NPC1RAB9ATSHR | |
| Bromide SCHEMBL28138957 | 0.82 | KMT2A (0.44) | NPC1RAB9ATSHR | |
| SCHEMBL7141260 | 0.81 | NPC1 (0.50) | NPC1RAB9AXDHLTA4HSCN4A | |
| SCHEMBL12735602 | 0.81 | PDGFRB (0.50) | NPC1RAB9A | |
| SCHEMBL17983446 | 0.80 | ENPP3 (0.36) | NPC1RAB9A | |
| SCHEMBL3747961 | 0.77 | CYP1A2 (0.49) | NPC1RAB9ATSHRCYP11B1CYP11B2 | |
| SCHEMBL19626728 | 0.77 | NPC1 (0.49) | NPC1RAB9AXDH | |
| SCHEMBL8250696 | 0.76 | METAP2 (0.44) | NPC1RAB9ANISCH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188133-B2 | Imidazole derivatives, preparation and user thereof as medicine | IPSEN PHARMA S.A.S. (FR) | 2012-05-29 | — | — | US | disclosed |
| US-20090186930-A1 | NOVEL IMIDAZOLE DERIVATIVES, PREPARATION AND USER THEREOF AS MEDICINE | SOCIETE DE CONSEILS DE RECHERCHES ET D' APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2009-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186930-A1 | NOVEL IMIDAZOLE DERIVATIVES, PREPARATION AND USER THEREOF AS MEDICINE | CYP51A1, IKZF3, MIF | NPC1 581/4885RAB9A 967/4885XDH 282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.